Kansas Clinical Trials Report — July 2026

Kansas residents who may qualify for a clinical trial should check closing studies now: 39 recruiting trials are expected to close within the next 90 days. Eight of those studies accept healthy volunteers, creating a limited window for people without a diagnosed condition. Enrollment dates can change, and screening may take time, so prospective participants should contact study sites as soon as possible.

Kansas has 875 recruiting trials across 43 cities and 448 research sites. The state added only 6 new trials in July, down sharply from 26 in May and 26 in June. That slowdown makes the trials that did open especially relevant for people seeking new opportunities, particularly in Kansas City, Lenexa, and Topeka.

Closing-soon studies span blood pressure, weight, cancer, and more

Hypertension is the most frequent condition among trials approaching closure, with 3 studies. Obesity, healthy participants, blood pressure, prostate cancer, and cardiovascular diseases each appear in 2 closing-soon trials. Other affected areas include type 1 diabetes, acute myeloid leukemia with mutated NPM1, acute stress disorder, and Crohn’s disease.

• Hypertension — 3 closing-soon trials
• Obesity, healthy participants, blood pressure, prostate cancer, and cardiovascular diseases — 2 each
• DM1, AML with mutated NPM1, acute stress disorder, and Crohn’s disease — 1 each

Healthy adults have two particularly time-sensitive categories of opportunity among the closing studies. Statewide, 87 trials are currently recruiting healthy volunteers, but only 1 of the six new July trials accepts them. People interested in paid or non-treatment research should therefore review eligibility promptly rather than wait for a larger wave of openings.

Patients with hypertension, obesity, prostate cancer, cardiovascular disease, or the listed blood disorders may also want to act now. A study’s projected closing date does not guarantee that every site will stop recruiting on that date, but it signals that available screening and enrollment opportunities may narrow soon.

July’s smaller group of new studies includes advanced drug trials

The six new Kansas trials cover AML, chronic obstructive pulmonary disease, limb-girdle muscular dystrophy type 2I, myelodysplastic syndromes, obesity and overweight, RSV, and smoking cessation. By intervention type, the new group includes 3 drug studies, 2 behavioral studies, 2 other interventions, and 1 biological intervention. The condition list is unusually varied for a small monthly intake, ranging from respiratory and infectious disease research to rare neuromuscular and blood cancers.

Several new studies stand out because of their Phase 2 or Phase 3 design, sponsor, or therapeutic focus:

• NCT07684820 — Expedition Therapeutics, Inc.’s Phase 2 COPD study of EXPD-101/FXS7553 versus placebo. The trial plans to enroll 600 participants and will evaluate efficacy, safety, tolerability, and pharmacokinetics over 52 weeks of once-daily treatment.
• NCT07702578 — TScan Therapeutics, Inc.’s Phase 3 study of T-cell receptor-engineered donor T cells for people undergoing allogeneic peripheral blood stem cell transplantation. The study plans to include 310 participants and will evaluate TSC-101 after reduced-intensity conditioning hematopoietic cell transplantation.
• NCT07678775 — ML Bio Solutions, Inc.’s Phase 3 open-label extension study of BBP-418, or ribitol, for limb-girdle muscular dystrophy type 2I/R9. It plans to enroll 107 participants who previously took part in the Fortify study and will assess long-term safety and efficacy.

NCT07684820 may be most relevant to adults living with COPD who are looking for a randomized medication study with a year-long treatment period. NCT07702578 is more specialized, requiring the transplant setting and relevant eligibility for cellular therapy research. NCT07678775 is designed for prior participants in a specific earlier study, so its availability will depend on that history.

The sponsor mix also gives July’s openings a strong industry presence. University of Kansas Medical Center sponsored 2 new trials. AstraZeneca, Expedition Therapeutics, Inc., ML Bio Solutions, Inc., and TScan Therapeutics, Inc. each sponsored 1. Four new trials were classified as industry-sponsored, two as other, and none as female-only or male-only studies.

Kansas City dominates new openings

New trial activity is concentrated in the Kansas City area. Kansas City opened 4 of the six new studies, while Lenexa and Topeka each opened 1. This means people living near the Kansas City metropolitan area have the widest immediate choice among July’s new opportunities.

• Kansas City — 4 new trials
• Lenexa — 1
• Topeka — 1

The broader recruiting landscape remains more geographically distributed than July’s new-trial list alone suggests: Kansas has active research in 43 cities and at 448 sites. However, the latest openings are clustered in a small number of locations, so patients outside Kansas City, Lenexa, and Topeka may need to search the full statewide database or consider travel to a participating site.

University of Kansas Medical Center’s role in two new studies also reinforces the importance of Kansas’s academic medical infrastructure. Academic centers can be especially relevant for complex oncology, transplant, rare-disease, and specialty-care trials, while industry-sponsored studies may offer access to investigational medicines being developed for broader patient populations.

Children and older adults have distinct openings

Only 1 of the new July trials includes children, and there are no newly opened female-only or male-only studies. Families should review the individual eligibility criteria carefully because a trial that includes children may still be limited to a particular age range or diagnosis.

Older adults are better represented: 5 new trials include older adults in their eligibility criteria. This may be relevant for people considering respiratory, cardiovascular, cancer, or other age-associated research, although age alone does not determine eligibility. Medical history, current medications, disease severity, prior treatment, and travel ability can all affect screening.

The monthly trend shows how quickly Kansas’s research pipeline can change: new recruiting trials numbered 17 in February, 18 in March, 15 in April, 22 in May, 26 in June, and 6 in July. A further 5 are recorded for August in the trend data, suggesting that people searching for options should revisit listings regularly instead of relying on a single monthly search.

For Kansas residents, the clearest next step is to match personal eligibility against the 39 studies nearing closure, then review the new COPD, transplant, rare-muscular-disease, blood-disorder, obesity, RSV, and smoking-cessation studies. As additional August listings develop, opportunities may expand beyond the current Kansas City-centered openings.